Opus Genetics Reports Q3 Earnings Miss on Lower Revenue and Negative EPS
Opus Genetics (IRD) reported third-quarter financial results that fell significantly short of market expectations. The company posted a GAAP earnings per share (EPS) of -$0.46, missing estimates by $0.31, while revenue totaled only $1.14 million, representing a 63% year-over-year decline and missing consensus by $0.94 million. Despite the earnings miss, management highlighted a strong cash position with an expected runway extending into 2029. This liquidity is intended to support upcoming clinical inflection points and potential opportunities regarding Priority Review Vouchers. The stock saw a slight downward movement in after-hours trading following the announcement.